Due to its inhibitory regulation of the TBK1/AKT axis, SIKE has been proposed as a negative regulator of cardiac remodeling in multiple animal species, and may represent a therapeutic target for the treatment of cardiac hypertrophy and heart failure [99]. The gene discussed is TBK1; the disease is cardiac hypertrophy.